Europe’s life sciences investors step up as biotech financing gap widens

EUROPEAN BIOTECHNOLOGY MAGAZINE - Europe produces world-class life sciences research, yet still struggles to finance and scale it. Venture capital in European biotech accounts for just 7 per cent of global funding, while 66 of the 67 EU biotech companies that went public over the past six years chose to list outside Europe. Capital is available globally; Europe is struggling to capture it. Read more

Photo by Maryna Yazbeck on Unsplash